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ABSTRACT
CONTEXT AND OBJECTIVE: Osteoporosis is a skeletal disorder characterized by low bone mineral density 
(BMD). Studies have shown that some of the genetic components relating to lower BMD may be detected 
by polymorphisms. Our aim was to evaluate the frequencies of interleukin-6, GST and progesterone recep-
tor gene polymorphisms in postmenopausal women with low BMD. 
DESIGN AND SETTING: Cross-sectional study, conducted in a public university in São Paulo, Brazil.
METHODS: We evaluated interleukin-6 (IL-6), progesterone receptor gene (PROGINS) and glutathione 
S-transferase (GST) polymorphisms in 110 postmenopausal women with no previous use of hormone 
therapy. Tests were performed using DNA-PCR, from oral scrapings. We used Student’s t-test and a logistic 
regression model for statistical analysis. 
RESULTS: Regarding IL-6 polymorphism, 58.2% of the patients were homozygotes (GG) and 41.8% had 
allele C (heterozygote or mutant homozygote + GC or CC). PROGINS genotype polymorphism was absent 
in 79% (wild homozygote or P1/P1) and present in 20.9% (heterozygote or P1/P2). Regarding GSTM1 
polymorphism, the allele (1/1) was present in 72.7% of the patients and was absent in 27.3%. We found 
that IL-6 polymorphism had statistically significant correlations with the L2-L4 T-score (P = 0.032) and with 
BMD (P = 0.005). Women with IL-6 polymorphism were 2.3 times more likely to have a L2-L4 T-score of less 
than -1, compared with those not presenting this polymorphism. 
CONCLUSION: IL-6 gene polymorphism was correlated with low BMD, whereas the PROGINS and GSTM1 
polymorphisms did not show any correlation. 
RESUMO
CONTEXTO E OBJETIVO: A osteoporose é uma desordem esquelética caracterizada por baixa densidade 
mineral óssea. Estudos têm demonstrado que alguns componentes genéticos relacionados com a menor 
densidade mineral óssea podem ser detectados por polimorfismos. Nosso objetivo foi avaliar a presença 
do polimorfismo de genes em mulheres pós-menopáusicas com baixa densidade mineral óssea.
TIPO DE ESTUDO E LOCAL: Estudo transversal, conduzido em universidade pública em São Paulo, Brasil.
MÉTODOS: Avaliamos os polimorfismos relacionados à interleucina-6 (IL-6), o gene receptor de 
progesterona (PROGINS) e glutationa S-transferase (GST) em 110 mulheres na pós-menopausa sem terapia 
hormonal prévia. Os testes foram realizados com DNA-PCR a partir de raspados orais. Foram utilizados 
teste t de Student e modelo de regressão logística para análise estatística.
RESULTADOS: Em relação ao polimorfismo IL-6, 58,2% dos pacientes eram homozigotos (GG) e 41,8% 
tinham o alelo C (heterozigoto ou homozigoto mutante + GC ou CC). Nos genótipos do polimorfismo 
PROGINS, 79% estavam ausentes (homozigoto selvagem ou P1/P1) e 20,9% presentes (heterozigoto ou 
P1/P2). No polimorfismo do GSTM1, o alelo (1/1) estava presente em 72,7% dos pacientes e ausente 
em 27,3%. Encontramos significância estatística entre o polimorfismo genético da IL-6 com o T-score de 
L2-L4 (P = 0,032) e a densidade mineral óssea (P = 0,005). As mulheres com polimorfismo da IL-6 tiveram 
2,3 vezes mais chance de ter menos de -1 na L2-L4 T-score, quando comparadas às não portadoras.
CONCLUSÃO: O polimorfismo do gene da IL-6 está correlacionado com baixa densidade mineral óssea, 
enquanto os polimorfismos GSTM1 e PROGINS não mostraram correlação.
IPostgraduate Student, Department of 
Gynecology, Universidade Federal de São Paulo –  
Escola Paulista de Medicina (Unifesp-EPM), São 
Paulo, Brazil.
IIMD, PhD. Adjunct Professor, Department of 
Gynecology, Universidade Federal de São Paulo –  
Escola Paulista de Medicina (Unifesp-EPM), São 
Paulo, Brazil.
IIIMD, PhD. Affiliated Professor, Department of 
Gynecology, Universidade Federal de São Paulo –  
Escola Paulista de Medicina (Unifesp-EPM), São 
Paulo, Brazil.
IVMD, PhD. Titular Professor, Department of 
Gynecology, Universidade Federal de São Paulo –  











Receptores de progesterona. 
Densidade óssea.
Pós-menopausa.
Frequencies of interleukin-6, GST and progesterone receptor gene polymorphisms in postmenopausal women with low bone mineral density | ORIGINAL ARTICLE
SSao Paulo Med J. 2014; 132(1):36-40    37
INTRODUCTION
Osteoporosis is a skeletal disorder characterized by low bone 
mineral density (BMD) and deterioration of bone microarchitec-
ture, thus predisposing towards a risk of fractures. It is estimated 
to affect more than 75 million people worldwide. The risk factors 
among women include: race, lower height, body mass index, low-
calcium diet, use of corticosteroids for over six months, smoking 
and menopausal status.1 
Earlier studies showed that environmental effects and genetic 
control influenced bone turnover.2,3 Back in 1991, genetic inheri-
tance was shown to be 45-85% likely to be a determinant of min-
eral density.2 Since then, various genes have been investigated.3-7 
Studies have shown that some of the genetic components relating 
to lower BMD may be detected by gene polymorphisms such as 
interleukin-6 (IL-6) polymorphism.8-11
IL-6 is a phosphoric acid-containing glycoprotein with 185 
amino acids and it is located in chromosome 7p21. It is a mul-
tifunctional cytokine produced by mononuclear cells and is 
regulated by the presence of polymorphisms. In fact, the C-G 
exchange in nucleotide 174 affects the transcription of this gene 
by decreasing its expression. IL-6 gene transcriptional activ-
ity is also marked in the presence of polymorphism in the pro-
moter region (174 G/C). Presence of the C allele mutant is asso-
ciated with low IL-6 plasma levels; however, presence of the G 
wild allele is related to high plasma levels of this cytosine.12 Some 
authors have observed increased IL-6 levels in postmenopausal 
women in response to lower levels of estradiol,13 and that gene 
polymorphism influenced bone resorption.14
Luo et al.15 reported that progesterone stimulated osteoblast 
proliferation and differentiation. This led to increased growth 
factors in osteoblasts, thus stimulating their proliferation and 
extracellular matrix synthesis. Progesterone receptor (PR) genes 
are located in the long arm of chromosome 11 (bands q22-23). 
Recently, variations in PR genes have been described, such as 
PROGINS. This polymorphism consists of an insertion of the 
Alu family, with a length of 306 base pairs (bp) in the G introns 
between exons 7 and 8. This event frequently occurs with two 
other mutations: replacement of a guanine base (G) with thymine 
(T) in exon 4, thereby exchanging a valine amino acid (Val) for 
leucine (Leu) in the receptor; and replacement of a cytosine base 
(C) with thymine (T) in exon 5.16,17 
Glutathione S-transferases (GSTs) are a family of enzymes 
that regulate conversion of toxic compounds to hydrophilic 
metabolites. GSTs are responsible for metabolization and per-
oxidation of estrogens and lipids, and their polymorphism fre-
quency is related to ethnic factors.18,19 There are three main genes 
involved in these polymorphisms: GSTM1, GSTT1 and GSTP1. 
GSTM1 is a gene located in chromosome 1p13.3 and is not 
expressed by 20% to 50% of individuals.18 Studies have suggested 
that genetic alterations such as in GSTM1 may increase the levels 
of estrogen and/or catechol estrogens, which might be associated 
with estrogen-dependent diseases.20,21
OBJECTIVE
The aim of our work was to estimate the frequencies of inter-
leukin-6, GST and progesterone receptor gene (PROGINS) 
polymorphisms in postmenopausal women with low BMD. 
METHODS
This was a cross-sectional study, conducted in a public university 
in São Paulo, Brazil, including 110 patients with no sample size 
calculation prior to the study initiation.
One hundred and ten women in their first ten years after the 
menopause (mean age of 52 years) were recruited. All patients 
provided their informed consent to participate in this study and 
the Local Ethics Committee approved the related protocol. This 
study was supported by the Department of Gynecology and there 
was no external sponsor. 
The inclusion criteria were that the women needed to have 
been postmenopausal for 5 to 10 years and needed to present 
follicle-stimulating hormone, FSH > 35 mUI/ml and estradiol 
< 20 pg/ml, and that a bone densitometry scan done before hor-
mone therapy needed to be available.
The exclusion criteria comprised absence of bone densitom-
etry before hormone therapy and no use of corticosteroids. None 
of the subjects had received any medication known to affect bone 
metabolism (such as glucocorticoids, thyroxin, anti-epileptics, 
bisphosphonates, calcitonin or hormone replacement therapy for 
more than three months).
All the subjects underwent careful physical examination and 
medical history review, including personal data, such as age, race, 
age at the menopause and medications currently used. Bone min-
eral density was evaluated using the Lunar DPX-L equipment 
(Lunar, Madison, Wisconsin, United States), which, according to 
the criterion of “z-bottom of form, z-top”, described by Kiebzak 
et al.,22 achieves a coefficient of variation of 0.62%. The measure-
ments were performed on the lumbar spine. The T-score and the 
Z-score were calculated. For comparison with polymorphisms, a 
T-score cutoff at -1 was used to define low bone mineral density. 
Samples of oral scrapings were collected using a cytobrush 
which was rubbed against the oral mucus lining and then placed 
in tubes containing tris-ethylenediaminetetraacetic acid (EDTA) 
buffer solution. The cytological samples thus obtained were pre-
served at -80 °C until subsequent extraction of the genomic 
deoxyribonucleic acid (DNA).
DNA extraction was performed in accordance with the 
Amersham-Pharmacia GFX kit protocol for oral cells. The DNA thus 
obtained was ready for use in the polymerase chain reaction (PCR). 
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The presence of IL-6, PROGINS and GSTM1 gene polymorphisms 
was investigated using primers that amplified a small DNA fragment 
containing the polymorphic site. The primer sequences used for the 
promoter region of the gene were as follows:
For interleukin 6: 5  ´- ATG CCA AGT GCT GAG TCA CTA - 3´ 
(sense) and 5  ´- GGA AAA TCC CAC ATT TGA TA - 3  ´(antisense). For 
PROGINS: 5  ´- GGC AGA AAG CAA AAT AAA AAG A - 3  ´(sense) and 
5  ´- AAA GTA TTT TCT TGC TAA ATG TC - 3  ´(antisense). For GSTM: 
5  ´- GAA CTC CCT GAA AAG CTA AAG C – 3  ´(sense) and 5  ´- GTT 
GGG CTC AAA TAT ACG GTG G – 3  ´(antisense).
Demographic and clinical variables were compared between 
genotype groups for the IL6, PROGINS and GSTM1 polymor-
phisms. Statistical analyses were performed using Student’s 
t-test or the Mann-Whitney test. Odds ratios and confidence 
intervals were derived from binary logistic regression analyses. 
The significance level was taken to be 0.05. To estimate the risks 
of the polymorphisms, a logistic regression model was applied 
to each polymorphism, using a 95% confidence interval.
RESULTS
In our population, 94% of the women were Caucasian. Regarding IL-6 
polymorphism, the composition of the groups was that 64 women 
were GG (homozygotes) and 48 were GC/CC (only two patients were 
CC). In relation to PROGINS, there were 87 women with P1/P1 (wild 
homozygotes) and 23 with positive PROGINS genotypes of the pro-
gesterone receptors, P1/P2 (heterozygote). The GSTM1 polymor-
phism analysis showed that in 30 women, the allele was absent (0/0) 
and, in 80 women, the allele genotype was present (1/1). 
Demographic and clinical variables were compared among 
homozygotes and heterozygotes for the IL6 genotype. There were 
significant differences in the L2/L4 T-score (P = 0.03) and BMD 
(P = 0.05) among the genotype groups (Table 1).
To facilitate the odds ratio calculation, the cutoff point 
for the L2/L4 T-score was adjusted to -1. In this manner, we 
found that women with polymorphism in one allele, i.e. who 
were heterozygous for IL-6, presented a risk of having a L2/L4 
T-score lower than -1.0 that was 2.3 times higher than those 
without this polymorphism.
No statistical differences were found between the genotype 
groups for the PROGINS and GSTM1 polymorphisms regarding 
clinical variables (Tables 2 and 3).
DISCUSSION
In our study, we found that G-C polymorphism in region 174 
of the IL-6 gene was associated with low bone mineral density. 
IL-6 is a cytokine with a crucial role in immune, inflammatory, 
hematopoietic and atherogenic responses and is associated with 
bone absorption. In bones, IL-6 is synthesized by osteoblasts, 
monocytes and T-cells, leading to differentiation and activation 
of osteoclasts. IL-1 and TNF-alpha have a role in activation, 
whereas estradiol and glucocorticoids suppress transcription of 
the IL-6 gene. Thus, the decreased estrogen levels in postmeno-
pausal women may trigger increased IL-6 expression, thus lead-
ing to bone mass loss.14
Several variations in alleles have been identified in the 
IL-6 promoter region. A common polymorphism, such as G-C 
exchange at position 174, may also interact with estrogen recep-
tors that regulate IL-6 expression. There is evidence that this 
polymorphism produces a functional variant in which the allele 
174C results in low stimulation of IL-6 and also in low concentra-




mean (± SD) mean (± SD)
Age (years) 110 51.57 (4.35) 52.50 (3.76) 0.24*
Weight (kg) 110 67.18 (12.18) 66.54 (12.84) 0.79*
Height (m) 110 1.53 (0.05) 1.53 (0.06) 0.95*
BMI (kg/m²) 110 28.44 (5.48) 28.02 (4.64) 0.67*
BMD (g/cm²) 110 1.13 (0.17) 1.07 (0.15) 0.05*
L2/L4 T-score 99 -0.40 (1.44) -1.04 (1.34) 0.03
†
Table 1. Clinical data regarding the interleukin-6 (IL-6) genotype. 
Values are given as the mean ± standard deviation (SD)





mean (± SD) mean (± SD)
Age (years) 110 51.78 (3.97) 52.65 (4.69) 0.37*
Weight (kg) 110 67.19 (12.90) 65.86 (10.38) 0.65*
Height (m) 110 1.54 (0.05) 1.53 (0.057) 0.50*
BMI (kg/m²) 110 28.31 (5.28) 28.11 (4.59) 0.87*
BMD (g/cm²) 110 1.11 (0.17) 1.09 (0.15) 0.62*
L2/L4 T-score 99 -0.60 (1.47) -0.89 (1.28) 0.47
†
Table 2. Clinical data regarding PROGINS. Values are given as 
the mean ± standard deviation (SD)





mean (± SD) mean (± SD)
Age (years) 110 51.46 (4.71) 52.15 (3.90) 0.44*
Weight (kg) 110 68.04 (10.47) 66.49 (13.09) 0.56*
Height (m) 110 1.53 (0.05) 1.54 (0.05) 0.59*
BMI (kg/m²) 110 28.96 (4.23) 28.01 (5.43) 0.38*
BMD (g/cm²) 110 1.12 (0.16) 1.10 (0.16) 0.58*
L2/L4 T-score 99 -0.53 (1.41) -0.72 (1.45) 0.76
†
Table 3. Clinical data regarding the GSTM1 genotype. Values 
are given as the mean ± standard deviation (SD)
*Student’s t; †Mann-Whitney; BMI = body mass index; BMD = bone 
mineral density.
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Czerny et al.23 studied associations between cytokine gene 
polymorphisms (IL-1 beta, IL-2 and IL-6) and BMD values in 
postmenopausal women. Their study included 226 postmeno-
pausal women with a diagnosed BMD T-score lower than -2.5 
standard deviations (SD) and 224 postmenopausal women with 
a BMD T-score greater than -2.5 SD. Among the women 
with T-scores below -2.5 SD, the BMD values were significantly 
lower in the carriers of the IL-6 GG genotype than in those with 
the CC and GC genotypes.
In a cohort of 559 postmenopausal Spanish women, two 
polymorphisms in the IL-6R promoter were analyzed in rela-
tion to BMD and body mass index. The authors reported that 
there was a significant association between polymorphisms of the 
IL-6R gene and BMD.24
On the other hand, Garnero et al.25 found that there were 
no significant associations between genotypes, bone turn-
over marker polymorphism and bone turnover or BMD in a 
cohort of healthy French women. They concluded that IL-6 
polymorphism was weakly associated with the peak BMD level 
and the rate of postmenopausal forearm trabecular bone loss. 
According to those authors, IL-6 genotypes accounted only for 
a small proportion of the variation of both peak BMD and rate 
of bone loss.
Even though no specific studies have reported polymor-
phisms of the PROGINS and GSTM1 genes in relation to BMD, 
we decided to study these polymorphisms. These occurrences 
can be explained by progesterone action on bone formation and 
the influence of GSTM1 on estrogen metabolization.
It has been implied that GSTs are important molecules involved 
in activation of cytoprotection genes18 and in correlation with the 
breast because of their ability to metabolize estrogens and lipids 
through peroxidation.20 This may also keep osteoporosis from 
manifesting, due to hyperestrogenism. This change to this gene 
could influence bone mass.
Some studies have observed that progesterone stimulates pro-
liferation of bone cells. This can be explained by increased insulin 
growth factor (IGF-2) levels, which could potentially stimulate 
proliferation of osteoblasts.15 Growth factor beta, together with 
insulinoid factor, is the most abundant growth factor in the bone, 
but the effect of progesterone on growth factor beta in osteoblasts 
is still unknown.26,27
In our study, we also evaluated PROGINS and GST gene poly-
morphisms regarding age, weight, IMC and BMD variables. We 
did not find any statistical correlation among them.
We reported that there was a significant association 
between polymorphisms of the IL-6 gene and BMD. The clini-
cal importance of these findings may lead to new directions 
for osteoporosis management, such as biomarkers and molec-
ular targets in therapeutics. 
However, in fact, there were several limitations to our 
study. It is possible that the sample size was inadequate for 
detecting small differences in the groups, and that the study 
power was suboptimal. Moreover, the lack of a matched con-
trol group consisting of women with normal BMD limits the 
conclusions of this study. It is important to reproduce this 
study in other populations in order to achieve better analysis 
and functional outcomes.
CONCLUSION
This study showed that there was a considerable frequency 
of polymorphisms of the IL-6 gene in women with low BMD. 
However, this was not found for the other genes under investi-
gation. Knowledge of osteoporosis-related genetic mechanisms 
may facilitate prevention and selection of women for therapeu-
tics and prognosis.
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